Statement from the Center for Innovation & Value Research on President Trump's July 31 Ultimatum on Most Favored Nation
The Center for Innovation & Value Research shares the public’s urgency in addressing the affordability of prescription drugs and healthcare in the United States. However, as momentum builds around aggressive policy proposals like the Most Favored Nation (MFN) pricing model, we urge policymakers to pause and ask a critical question: What do these policies mean for patients?
As we have emphasized in our public comments, drug pricing reform must be grounded in patient-centered value, not simply cost containment. Models like MF and Internal Reference Pricing (IRP) risk importing foreign solutions into a deeply complex U.S. healthcare system without accounting for patient heterogeneity, disparities in access, or real-world outcomes that matter most to patients and caregivers.
The Center supports bold action on affordability. But lasting, equitable solutions require transparent, evidence-based policymaking that reflects what patients truly value: timely access, choice, quality of life, and sustainability of innovation.
In October, we will bring together policymakers, patients, researchers, and global experts for a full-day, in-person convening in Washington, D.C., to identify patient-informed, actionable alternatives to blunt pricing mandates like MFN. Our goal is to shape reforms that are not only economically sound, but equitable, inclusive, and rooted in the lived experiences of those most affected.
We look forward to continuing this critical dialogue and supporting policymakers in advancing drug pricing policies that prioritize both access and value.
